Last reviewed · How we verify
TSR-011
At a glance
| Generic name | TSR-011 |
|---|---|
| Also known as | ALK inhibitor, ALKi, TRK inhibitor |
| Sponsor | Tesaro, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSR-011 CI brief — competitive landscape report
- TSR-011 updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI